The history of clotting factor concentrates pharmacokinetics

Journal of Clinical Medicine

Volumn 6, Issue 3, 2017, Pages

  Morfini, Massimo ^a  

^a Italian Association of Haemophilia Centres (AICE)   (Italy)

Author keywords

Bayesian compromise; Clearance; Clotting factor concentrates; Compartment methods; Half life; In vivo recovery; Non compartment analysis; Pharmacokinetics; PopPK; Prophylaxis; Volume of distribution

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING FACTOR CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 8;

AREA UNDER THE CURVE; BAYES THEOREM; BIOEQUIVALENCE; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; HEMOPHILIA; HUMAN; IN VIVO RECOVERY; NONHUMAN; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PHARMACOLOGICAL SCIENCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POPULATION PHARMACOKINETICS; PROPHYLAXIS; RECOMBINANT DNA TECHNOLOGY; REVIEW;

EID: 85040699646     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm6030035     Document Type: Review

References (89)

1. Gibaldi, M.; Perrier, D. Pharmacokinetics; Marcel Dekker: New York, NY, USA, 1975.
2. Pool, J.G.; Hink, J.H. Experiences in the preparation of AHG concentrates from human plasma. Bibl Haematol. 1964, 19, 146-150. [PubMed]
3. Pool, J.C.; Shannon, A.E. Production of high-potency concentrates of anti-haemophilic globulin in a closed bag system. N. Engl. J. Med. 1965, 273, 1443. [CrossRef] [PubMed]
4. Nilsson, I.M. Management of haemophilia in Sweden. Thromb. Haemost. 1976, 35, 510-521. [PubMed]
5. Allain, J.P.; Verroust, F.; Soulier, J.P. In vitro and in vivo characterization of factor VIII preparations. Vox Sang. 1980, 38, 68-80. [CrossRef] [PubMed]
6. Kjellman, H. Calculations of factor VIII in vivo recovery and half-life. Scand. J. Haematol. Suppl. 1984, 40, 165-174. [CrossRef] [PubMed]
7. Nilsson, I.M.; Hedner, U. Characteristics of various factor VIII concentrates used in treatment of haemophilia A. Br. J. Haematol. 1977, 37, 543-557. [CrossRef] [PubMed]
8. Prowse, C.V. In vivo recovery of factor VIII following transfusion, a survey of recent data and publications to assess the influence of standards used for potency assignment. On behalf of the Subcommittee on Factor VIII and IX of the Scientific and Standardization Committee of the ISTH. Thromb. Haemost. 1995, 74, 1191-1196. [PubMed]
9. Björkman, S.; Folkesson, A.; Berntorp, E. In vivo recovery of factor VIII and factor IX, intra- and interindividual variance in a clinical setting. Haemophilia 2007, 13, 2-8. [CrossRef] [PubMed]
10. Kasper, C.K.; Kipnis, S.A. Hepatitis and clotting-factor concentrates. JAMA 1972, 221, 510. [CrossRef] [PubMed]
11. Craske, J.; Dilling, N.; Stern, D. An outbreak of hepatitis associated with intravenous injection of factor-VIII concentrate. Lancet 1975, 2, 221-223. [CrossRef]
12. Morfini, M.; Longo, G.; Matucci, M.; Vannini, S.; Messori, A.; Filimberti, E.; Duminuco, M.; Avanzi, G.; Rossi-Ferrini, P. Cryoprecipitate and Factor VIII commercial concentrates, in vitro characteristics and in vivo compartmental analysis. Ric. Clin. Lab. 1984, 14, 681-691. [PubMed]
13. Morfini, M.; Messori, A.; Longo, G.; Matucci, M.; Rossi-Ferrini, P. Pharmacokinetics of three heat-treated concentrates of Factor VIII. In FVIII and von Willebrand Biological and Clinical Advances; Ciavarella, N., Ruggeri, Z., Zimmerman, T., Eds.;Witchig: Milan, Italy, 1985; pp. 303-307.
14. Messori, A.; Longo, G.; Morfini, M.; Cinotti, S.; Filimberti, E.; Giustarini, G.; Rossi Ferrini, P. Multi-variate analysis of factors governing the pharmacokinetics of exogenous factor VIII in haemophiliacs. Eur. J. Clin. Pharmacol. 1988, 35, 663-668. [CrossRef] [PubMed]
15. Ingram, G.I. Calculating the dose of factor VIII in the management of haemophilia. Br. J. Haematol. 1981, 48, 351-354. [CrossRef] [PubMed]
16. Den Uijl, I.E.; Fischer, K.; Van Der Bom, J.G.; Grobbee, D.E.; Rosendaal, F.R.; Plug, I. Analysis of low frequency bleeding data, the association of joint bleeds according to baseline FVIII activity levels. Haemophilia 2011, 17, 41-44. [CrossRef] [PubMed]
17. Sawchuk, R.J.; Zaske, D.E.; Cipolle, R.J.; Wargin, W.A.; Strate, R.G. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin. Pharmacol. Ther. 1977, 21, 362-369. [CrossRef] [PubMed]
18. Sheiner, L.B.; Rosenberg, B.; Melmon, K.L. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput. Biomed. Res. 1972, 5, 411-459. [CrossRef]
19. Sheiner, L.B.; Beal, S.; Rosenberg, B.;Marathe, V.V. Forecasting individual pharmacokinetics. Clin. Pharmacol. Ther. 1979, 26, 294-305. [CrossRef] [PubMed]
20. Longo, G.; Messori, A.; Morfini, M.; Baudo, F.; Ciavarella, N.; Cinotti, S.; Filimberti, E.; Giustarini, G.; Molinari, A.C.; Ferrini, P.R. Evaluation of factor VIII pharmacokinetics in hemophilia-A subjects undergoing surgery and description of a nomogram for dosing calculations. Am. J. Hematol. 1989, 30, 140-149. [CrossRef] [PubMed]
21. Messori, A.; Longo, G.; Morfini, M.; Donati-Cori, G.; Matucci, M.; Ruffo, S.; Tendi, E.; Vannini, S. Individualization of Factor VIII dosage. J. Clin. Hosp. Pharm. 1984, 9, 95-103. [CrossRef] [PubMed]
22. Ruffo, S.; Messori, A.; Longo, G.; Matucci, M.; Morfini, M.; Rossi-Ferrini, P. A microcomputer program for individualizing factor VIII dosage in hemophilia patients undergoing major surgery. Comput. Methods Progr. Biomed. 1986, 23, 37-46. [CrossRef]
23. Ruffo, S.; Messori, A.; Grasela, T.H.; Longo, G.; Donati-Cori, G.; Matucci, M.; Morfini, M.; Tendi, E. A calculator program for clinical application of the Bayesian method of predicting plasma drug levels. Comput. Progr. Biomed. 1985, 19, 167-177. [CrossRef]
24. Ruffo, S.; Matucci, M.; Longo, G.; Morfini, M.; Vannini, S.; Messori, A.; Donati-Cori, G.; Tendi, E.; Valenza, T.; Zaccara, G.; et al. A weighted least-squares approach for fitting to kinetic models the plasma concentration data of phenytoin and Factor VIII. Farmaco Prat 1984, 39, 211-221. [PubMed]
25. Matucci, M.; Messori, A.; Donati-Cori, G.; Longo, G.; Vannini, S.; Morfini, M.; Tendi, E.; Rossi-Ferrini, P.L. Kinetic evaluation of four Factor VIII concentrates by model-independent methods. Scand. J. Haematol. 1985, 34, 22-28. [CrossRef] [PubMed]
26. Morfini, M.; Marchesini, E.; Paladino, E.; Santoro, C.; Zanon, E.; Iorio, A. Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates, a comparative study. Haemophilia 2015, 21, 204-209. [CrossRef] [PubMed]
27. Gabielsson, J.;Weiner, D. Pharmacokinetic and Pharmacodynamic Data Analysis-Concept and Application, 3rd ed.; Swedish Pharmaceutical Press: Stockholm, Sweden, 1994.
28. Morfini, M.; Mannucci, P.M.; Longo, G.; Cinotti, S.; Messori, A. Comparative evaluation of the pharmacokinetics of three monoclonal factor VIII concentrates. Thromb. Res. 1991, 61, 285-290. [CrossRef]
29. Morfini, M.; Mannucci, P.M.; Tenconi, P.M.; Longo, G.; Mazzucconi, M.G.; Rodeghiero, F.; Ciavarella, N.; De Rosa, V.; Arter, A. Pharmacokinetics of monoclonally-purified and recombinant factor VIII in patients with severe vonWillebrand disease. Thromb. Haemost. 1993, 70, 270-272. [PubMed]
30. Lethagen, S.; Berntorp, E.; Nilsson, I.M. Pharmacokinetics and hemostatic effect of different factor VIII/von Willebrand factor concentrates in von Willebrand’s disease type III. Ann. Hematol. 1992, 65, 253-259. [CrossRef] [PubMed]
31. Terraube, V.; O’Donnell, J.S.; Jenkins, P.V. Factor VIII and von Willebrand factor interaction, biological, clinical and therapeutic importance. Haemophilia 2010, 16, 3-13. [CrossRef] [PubMed]
32. Over, J.; Sixma, J.J.; Bruïne, M.H.; Trieschnigg, M.C.; Vlooswijk, R.A.; Beeser-Visser, N.H.; Bouma, B.N. Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human Factor VIII. J. Clin. Investig. 1978, 62, 223-234. [CrossRef] [PubMed]
33. Morfini, M.; Lee, M.; Messori, A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Thromb. Haemost. 1991, 66, 384-386. [PubMed]
34. Lee,M.;Morfini,M.; Schulman, S.; Ingerslev, J. The Factor VIII/Factor IX SSC of ISTH. The Design and Analysis of Pharmacokinetic Studies of Coagulation Factors. Available online: https://c.ymcdn.com/sites/www.isth. org/resource/group/d4a6f49a-f4ec-450f-9e0f-7be9f0c2ab2e/official_communications/fviiipharmaco.pdf (accessed on 29 January 2017).
35. Barrowcliffe, T.W.; Raut, S.; Hubbard, A.R. Discrepancies in potency assessment of recombinant FVIII concentrates. Haemophilia 1998, 4, 634-640. [PubMed]
36. Raut, S.; Sands, D.; Heath, A.B.; Barrowcliffe, T.W. Variability in factor VIII concentrate measurement, results from SSC field collaborative studies. J. Thromb. Haemost. 2003, 1, 1927-1934. [CrossRef] [PubMed]
37. Kitchen, S.; Signer-Romero, K.; Key, N.S. Current laboratory practices in the diagnosis and management of haemophilia, a global assessment. Haemophilia 2015, 21, 550-557. [CrossRef] [PubMed]
38. Kitchen, S.; Jennings, I.; Makris, M.; Kitchen, D.P.; Woods, T.A.; Walker, I.D. Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII. Haemophilia 2016, 22, 806-812. [CrossRef] [PubMed]
39. Blombäck, M.; Kjellman, H.; Allain, J.P.; Hedner, U.; Schimpf, K.;Wiechel, B. On the unreliability of one-stage factor VIII, C clotting assays after infusion of factor VIII concentrates. Scand. J. Clin. Lab. Investig. 1987, 47, 561-566. [CrossRef]
40. Cinotti, S.; Longo, G.; Messori, A.; Morfini, M.; Blomback, M.; Schimpf, K.; Schumacher, K.; Kjellman, H.; Novakova-Banet, A.; Delvos, U. Reproducibility of one-stage, two-stage and chromogenic assays of factor VIII activity, a multi-center study. Thromb. Res. 1991, 61, 385-393. [CrossRef]
41. Messori, A.; Morfini, M.; Blomback, M.; Cinotti, S.; Longo, G.; Schimpf, K.; Schumacher, K.; Novakova-Banet, A.; Delvos, U.; Kjellman, H. Pharmacokinetics of two pasteurized factor VIII concentrates by different and multicenter assays of factor VIII activity. Thromb. Res. 1992, 65, 699-708. [CrossRef]
42. Morfini, M.; Cinotti, S.; Bellatreccia, A.; Paladino, E.; Gringeri, A.; Mannucci, P.M.; ReFacto-AICE Study Group. A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards. J. Thromb. Haemost. 2003, 1, 2283-2289. [CrossRef] [PubMed]
43. Lollar, P. The factor VIII assay problem, neither rhyme nor reason. J. Thromb. Haemost. 2003, 1, 2275-2279. [CrossRef] [PubMed]
44. Morfini, M.; Longo, G.; Messori, A.; Lee, M.; White, G.; Mannucci, P. Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil M). The Recombinate Study Group. Thromb. Haemost. 1992, 68, 433-435. [PubMed]
45. Cinotti, S.; Paladino, E.; Morfini, M. Accuracy of FVIII, C assay by one-stage method can be improved using hemophilic plasma as diluent. J. Thromb. Haemost. 2006, 4, 828-833. [CrossRef] [PubMed]
46. Morfini, M.; Longo, G.; Berntorp, E.; Cinotti, S.; Filimberti, E.; Messori, A.; Nilsson, I.M.; Rossi Ferrini, P. Pharmacokinetics, thrombogenicity and safety of a double-treated prothrombin complex concentrate. Thromb. Res. 1993, 71, 175-184. [CrossRef]
47. Poon, M.C.; Aledort, L.M.; Anderle, K.; Kunschak, M.; Morfini, M. Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. Transfusion 1995, 35, 319-323. [CrossRef] [PubMed]
48. Morfini, M.; Laguna, P.; Leissinger, C. Factor IX pharmacokinetics, differences between plasma-derived and recombinant products and the clinical and economic implications, a meeting report. Haemophilia 2008, 14, 873-875. [CrossRef] [PubMed]
49. Longo, G.; Cinotti, S.; Filimberti, E.; Giustarini, G.; Messori, A.; Morfini, M.; Ferrini, P.R. Single-dose pharmacokinetics of factor IX evaluated by model-independent methods. Eur. J. Haematol. 1987, 39, 426-433. [CrossRef] [PubMed]
50. Thomas, D.P. Pharmacokinetic studies on a new purified factor IX concentrate. Haemophilia 1995, 2, 23-25. [CrossRef] [PubMed]
51. Goudemand, J.; Peynet, J.; Chambost, H.; Négrier, C.; Briquel, M.E.; Claeyssens, S.; Derlon-Borel, A.; Guérois, C.; Caron, C.; Scherrmann, J.M.; et al. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate. Thromb. Haemost. 1998, 80, 919-924. [PubMed]
52. Björkman, S.; Carlsson, M.; Berntorp, E.; Stenberg, P. Pharmacokinetics of factor VIII in humans. Obtaining clinically relevant data from comparative studies. Clin. Pharmacokinet. 1992, 22, 385-395. [CrossRef] [PubMed]
53. Nilsson, I.M.; Berntorp, E.; Löfqvist, T.; Pettersson, H. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and, B. J. Intern. Med. 1992, 232, 25-32. [CrossRef] [PubMed]
54. Carlsson, M.; Berntorp, E.; Björkman, S.; Lindvall, K. Pharmacokinetic dosing in prophylactic treatment of hemophilia A. Eur. J. Haematol. 1993, 51, 247-252. [CrossRef] [PubMed]
55. Carlsson, M.; Berntorp, E.; Björkman, S.; Lethagen, S.; Ljung, R. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia 1997, 3, 96-101. [CrossRef] [PubMed]
56. Carlsson, M.; Björkman, S.; Berntorp, E. Multidose pharmacokinetics of factor IX; implications for dosing in prophylaxis. Haemophilia 1998, 4, 83-88. [CrossRef] [PubMed]
57. Lindvall, K.; Astermark, J.; Björkman, S.; Ljung, R.; Carlsson, K.S.; Persson, S.; Berntorp, E. Daily dosing prophylaxis for haemophilia, a randomized crossover pilot study evaluating feasibility and efficacy. Haemophilia 2012, 18, 855-859. [CrossRef] [PubMed]
58. Björkman, S.; Carlsson, M.; Berntorp, E. Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation. Eur. J. Clin. Pharmacol. 1994, 46, 325-332. [CrossRef]
59. Feng, D.; Stafford, K.A.; Broze, G.J.; Stafford, D.W. Evidence of clinically significant extravascular stores of factor IX. J. Thromb. Haemost. 2013, 11, 2176-2178. [CrossRef] [PubMed]
60. Gui, T.; Lin, H.F.; Jin, D.Y.; Hoffman, M.; Straight, D.L.; Roberts, H.R.; Stafford, D.W. Circulating and binding characteristics of wild-type factor IX and certain Gladomain mutants in vivo. Blood 2002, 100, 153-158. [CrossRef] [PubMed]
61. Björkman, S. Comparative pharmacokinetics of factor VIII and recombinant factor IX, for which coagulation factors should half-life change with age? Haemophilia 2013, 19, 882-886. [CrossRef] [PubMed]
62. White, G.C., 2nd; Beebe, A.; Nielsen, B. Recombinant factor IX. Thromb. Haemost. 1997, 78, 261-265. [PubMed]
63. White, G.C., 2nd; Shapiro, A.; Ragni, M.; Garzone, P.; Goodfellow, J.; Tubridy, K.; Courter, S. Clinical evaluation of recombinant factor IX. Semin. Hematol. 1998, 35, 33-38. [PubMed]
64. Roth, D.A.; Kessler, C.M.; Pasi, K.J.; Rup, B.; Courter, S.G.; Tubridy, K.L. Recombinant Factor IX Study Group. Human recombinant factor IX, safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001, 98, 3600-3606. [CrossRef] [PubMed]
65. Ewenstein, B.M.; Joist, J.H.; Shapiro, A.D.; Hofstra, T.C.; Leissinger, C.A.; Seremetis, S.V.; Broder, M.; Mueller-Velten, G.; Schwartz, B.A.; Mononine Comparison Study Group. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002, 42, 190-197. [CrossRef] [PubMed]
66. Björkman, S.; Shapiro, A.D.; Berntorp, E. Pharmacokinetics of recombinant factor IX in relation to age of the patient, implications for dosing in prophylaxis. Haemophilia 2001, 7, 133-139. [CrossRef] [PubMed]
67. Chow, S.C.; Liu, J.P. Design and Analysis of Bioavailability and Bioequivalence Studies; Marcel Dekker: New York, NY, USA, 1992; pp. 48-69.
68. Lee, C.A. Pharmacokinetic studies in patients with inherited bleeding disorders-Challenges and relevance to clinical practice. Haemophilia 2006, 12, 1-2. [CrossRef] [PubMed]
69. Morfini, M. Pharmacokinetic studies, international guidelines for the conduct and interpretation of such studies. Haemophilia 2006, 12, 6-11. [CrossRef]
70. Stass, H. Determination of minimal sampling time points for reliable pharmacokinetic evaluation of recombinant factor VIII-An exploratory population pharmacokinetic analysis in paediatric patients suffering from severe haemophilia. Haemophilia 2006, 12, 50-55. [CrossRef]
71. Björkman, S.; Blanchette, V.S.; Fischer, K.; Oh, M.; Spotts, G.; Schroth, P.; Fritsch, S.; Patrone, L.; Ewenstein, B.M.; Advate Clinical Program Group; et al. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults, the influence of blood sampling schedule on observed age-relateddifferences and implications for dose tailoring. J. Thromb. Haemost. 2010, 8, 730-736.
72. Negrier, C.; Knobe, K.; Tiede, A.; Giangrande, P.; Møss, J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX, a first human dose trial in patients with hemophilia B. Blood 2011, 118, 2695-2701. [CrossRef] [PubMed]
73. Santagostino, E.; Negrier, C.; Klamroth, R.; Tiede, A.; Pabinger-Fasching, I.; Voigt, C.; Jacobs, I.; Morfini, M. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012, 120, 2405-2411. [CrossRef] [PubMed]
74. Powell, J.S.; Pasi, K.J.; Ragni, M.V.; Ozelo, M.C.; Valentino, L.A.; Mahlangu, J.N.; Josephson, N.C.; Perry, D.; Manco-Johnson, M.J.; Apte, S.; et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N. Engl. J. Med. 2013, 369, 2313-2323. [CrossRef] [PubMed]
75. Morfini, M.; Dragani, A.; Paladino, E.; Radossi, P.; Di Minno, G.; Mazzucconi, M.G.; Rossetti, G.; Barillari, G.; Napolitano, M.; Tagariello, G. Correlation between FIX genotype and pharmacokinetics of Nonacog alpha according to a multicentre Italian study. Haemophilia 2016, 22, 537-542. [CrossRef] [PubMed]
76. Hua, B.; Wu, R.; Alvey, C.; Labadie, R.; Peng, R.; Korth-Bradley, J.; Rendo, P. Confirmation of longer FIX activity half-life with prolonged sample collection after single doses of nonacog alfa in patients with haemophilia B. Thromb. Haemost. 2017, accepted for publication.
77. Messori, A.; Longo, G.; Matucci, M.; Morfini, M.; Ferrini, P.L. Clinical pharmacokinetics of factor VIII in patients with classic haemophilia. Clin. Pharmacokinet. 1987, 13, 365-380. [CrossRef] [PubMed]
78. Collins, P.W.; Björkman, S.; Fischer, K.; Blanchette, V.; Oh, M.; Schroth, P.; Fritsch, S.; Casey, K.; Spotts, G.; Ewenstein, B.M. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A, influences of variance in pharmacokinetics and treatment regimens. J. Thromb. Haemost. 2010, 8, 269-275. [CrossRef] [PubMed]
79. Valentino, L.A.; Pipe, S.W.; Collins, P.W.; Blanchette, V.S.; Berntorp, E.; Fischer, K.; Ewenstein, B.M.; Oh, M.; Spotts, G. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis. Haemophilia 2016, 22, 514-520. [CrossRef] [PubMed]
80. Morfini, M.; Grasela, T.H.; Longo, G.; Matucci, M.; Messori, A.; Vannini, S.; Rossi-Ferrini, P. Comparison of two pharmacokinetic techniques for individualizing factor VIII dosage in haemophilia patients. Haematologica 1985, 70, 454-456. [PubMed]
81. Riviere, J.E. Comparative Pharmacokinetics, Principles, Techniques and Application; Wiley-Blackwell: Chichester, UK, 2011.
82. Iorio, A.; Keepanasseril, A.; Foster, G.; Navarro-Ruan, T.; McEneny-King, A.; Edginton, A.N.; Thabane, L. Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo), Study Protocol. JMIR Res. Protoc. 2016, 5, e239. [CrossRef] [PubMed]
83. Björkman, S.; Oh, M.; Spotts, G.; Schroth, P.; Fritsch, S.; Ewenstein, B.M.; Casey, K.; Fischer, K.; Blanchette, V.S.; Collins, P.W. Population pharmacokinetics of recombinant factor VIII, the relationships of pharmacokinetics to age and body weight. Blood 2012, 119, 612-618. [CrossRef] [PubMed]
84. Björkman, S.; Ahlén, V. Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B, implications for dosing in prophylaxis. Eur. J. Clin. Pharmacol. 2012, 68, 969-977. [CrossRef] [PubMed]
85. Brekkan, A.; Berntorp, E.; Jensen, K.; Nielsen, E.I.; Jönsson, S. Population pharmacokinetics of plasma-derived factor IX, procedures for dose individualization. J. Thromb. Haemost. 2016, 14, 724-732. [CrossRef] [PubMed]
86. Gringeri, A.; Wolfsegger, M.; Steinitz, K.N.; Reininger, A.J. Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis-New insight provided by pharmacokinetic modelling. Haemophilia 2015, 21, 300-306. [CrossRef] [PubMed]
87. Carcao, M. Switching from current factor VIII to longer acting FVIII concentrates, what is the real potential benefit? Haemophilia 2015, 21, 297-299. [CrossRef] [PubMed]
88. Hastings, W.K. Monte Carlo sampling methods using Markov chains and their applications. Biometrika 1970, 57, 97-109. [CrossRef]
89. Collins, P.; Chalmers, E.; Chowdary, P.; Keeling, D.; Mathias, M.; O’Donnell, J.; Pasi, K.J.; Rangarajan, S.; Thomas, A. The use of enhanced half-life coagulation factor concentrates in routine clinical practice, guidance from UKHCDO. Haemophilia 2016, 22, 487-498. [CrossRef] [PubMed]